[{"address1": "60-66 Hanover Street", "city": "Fitzroy", "state": "VIC", "zip": "3065", "country": "Australia", "phone": "61 3 8412 7000", "fax": "61 3 8412 7040", "website": "https://genetype.com", "industry": "Diagnostics & Research", "sector": "Healthcare", "longBusinessSummary": "Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates through AffinityDNA, EasyDNA, and GeneType/Corporate segments. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, type 2 diabetes, pancreatic cancer, melanoma, and atrial fibrillation. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne for the development and commercialization of a novel colorectal cancer risk assessment test; and Memorial Sloan Kettering Cancer Center of New York and University of Cambridge, that assess the conflict among BRCA mutation carriers considering preventive surgery. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.", "fullTimeEmployees": 60, "companyOfficers": [{"maxAge": 1, "name": "Mr. Simon  Morriss", "title": "Chief Executive Officer", "fiscalYear": 2023, "totalPay": 259442, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Carl S. Stubbings BSc", "title": "Chief Commercial Officer", "fiscalYear": 2023, "totalPay": 171856, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kevin  Camilleri", "title": "Chief Executive Officer of EasyDNA", "fiscalYear": 2023, "totalPay": 165856, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark  Ziirsen", "age": 60, "title": "CFO & Company Secretary", "yearBorn": 1963, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Paul Keith Mathieson Viney B. Bus, FCI, FCPA, FGIA", "title": "Consultant", "fiscalYear": 2023, "totalPay": 118106, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.7937, "open": 0.787, "dayLow": 0.77, "dayHigh": 0.8723, "regularMarketPreviousClose": 0.7937, "regularMarketOpen": 0.787, "regularMarketDayLow": 0.77, "regularMarketDayHigh": 0.8723, "beta": 0.508, "volume": 68505, "regularMarketVolume": 68505, "averageVolume": 81022, "averageVolume10days": 57400, "averageDailyVolume10Day": 57400, "bid": 0.8021, "ask": 0.8844, "bidSize": 100, "askSize": 100, "marketCap": 2778542, "fiftyTwoWeekLow": 0.75, "fiftyTwoWeekHigh": 4.65, "priceToSalesTrailing12Months": 0.2712608, "fiftyDayAverage": 1.5728, "twoHundredDayAverage": 2.44245, "currency": "USD", "enterpriseValue": 94988608, "profitMargins": -1.24083, "floatShares": 12795156, "sharesOutstanding": 3219090, "sharesShort": 19580, "sharesShortPriorMonth": 76321, "sharesShortPreviousMonthDate": 1718323200, "dateShortInterest": 1721001600, "sharesPercentSharesOut": 0.0061000003, "heldPercentInstitutions": 0.01368, "shortRatio": 0.21, "bookValue": 0.042, "priceToBook": 20.285715, "lastFiscalYearEnd": 1688083200, "nextFiscalYearEnd": 1719705600, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -12709889, "trailingEps": -0.15, "lastSplitFactor": "1:4", "lastSplitDate": 1565827200, "enterpriseToRevenue": 9.273, "enterpriseToEbitda": -9.636, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "GENE", "underlyingSymbol": "GENE", "shortName": "Genetic Technologies Ltd", "longName": "Genetic Technologies Limited", "firstTradeDateEpochUtc": 1126013400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "1fb68761-2b24-3dda-ac8c-b9635b9462c6", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.852, "recommendationKey": "none", "totalCash": 3729200, "totalCashPerShare": 0.032, "ebitda": -9857421, "totalDebt": 382317, "quickRatio": 1.416, "currentRatio": 1.67, "totalRevenue": 10243065, "debtToEquity": 7.945, "revenuePerShare": 2.73, "returnOnAssets": -0.52709, "returnOnEquity": -1.6047, "freeCashflow": -4598802, "operatingCashflow": -7603042, "revenueGrowth": -0.021, "grossMargins": 0.61495996, "ebitdaMargins": -0.96235, "operatingMargins": -1.05958, "financialCurrency": "AUD", "trailingPegRatio": null, "__fetch_time": "2024-07-29"}]